Crystalline forms of a macrolide, and uses therefor

Abstract

New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.

1 .- 32 . (canceled) 
     
     
         33 . A composition comprising solithromycin in crystalline form characterized by differential scanning calorimetry having an endotherm at about 170° C., an endotherm in the range from about 194° C. to about 199° C., an endotherm in the range from about 219° C. to about 225° C., an endotherm at about 225° C., or a combination thereof. 
     
     
         34 . The composition of  claim 33  characterized by differential scanning calorimetry having an endotherm in the range from about 197° C. to about 198° C. 
     
     
         35 . The composition of  claim 33  characterized by differential scanning calorimetry having an endotherm at about 225° C. 
     
     
         36 . The composition of  claim 33  characterized by differential scanning calorimetry having an endotherm in the range from about 194° C. to about 199° C., and an endotherm in the range from about 219° C. to about 225° C. 
     
     
         37 . A composition comprising solithromycin in crystalline Form I characterized by X-ray powder diffraction pattern including a peak at ° 2θ=6.2, 8.5, or 8.8, each ±0.2 °2θ, or a combination thereof; and optionally solithromycin in crystalline Form II characterized by X-ray powder diffraction pattern including a peak at ° 2θ=5.6 or 7.9, each ±0.2 °2θ, or a combination thereof. 
     
     
         38 . The composition of  claim 37  wherein the ratio of Form I to Form II is about 90:10 or greater. 
     
     
         39 . The composition of  claim 37  wherein the ratio of Form I to Form II is about 95:5 or greater. 
     
     
         40 . The composition of  claim 37  wherein the ratio of Form I to Form II is about 98:2 or greater. 
     
     
         41 . The composition of  claim 37  wherein the ratio of Form I to Form II is about 99:1 or greater. 
     
     
         42 . A composition comprising solithromycin in crystalline Form II characterized by X-ray powder diffraction pattern including a peak at ° 2θ=5.6 or 7.9, each ±0.2 °2θ, or a combination thereof; and optionally solithromycin in crystalline Form I characterized by X-ray powder diffraction pattern including a peak at ° 2θ=6.2, 8.5, or 8.8, each ±0.2 °2θ, or a combination thereof. 
     
     
         43 . The composition of  claim 42  wherein the ratio of Form II to Form I is 90:10 or greater. 
     
     
         44 . The composition of  claim 42  wherein the ratio of Form II to Form I is 95:5 or greater. 
     
     
         45 . The composition of  claim 42  wherein the ratio of Form II to Form I is 98:2 or greater. 
     
     
         46 . The composition of  claim 42  wherein the ratio of Form II to Form I is 99:1 or greater. 
     
     
         47 . A method of treatment of a bacterial infection, a protozoal infection, or a disorder caused at least in party by a bacterial infection or protozoal infection in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of the composition of  claim 33 , optionally further comprising at least one pharmaceutically acceptable carrier, diluent, or excipient, or a combination thereof.